利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.03 秒)

    Highly selective norepinephrine reuptake inhibitors and methods of using the same
    1.
    发明授权
    Highly selective norepinephrine reuptake inhibitors and methods of using the same 失效
    高选择性去甲肾上腺素再摄取抑制剂及其使用方法

    公开(公告)号：US07723334B2

    公开(公告)日：2010-05-25

    申请号：US11928917

    申请日：2007-10-30

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31/5375 ,  A61P25/22 ,  A61P25/24 ,  A61P25/32 ,  A61P3/04

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    Method of treating chronic pain
    3.
    发明授权
    Method of treating chronic pain 失效
    治疗慢性疼痛的方法

    公开(公告)号：US06703389B2

    公开(公告)日：2004-03-09

    申请号：US10020261

    申请日：2001-12-14

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31535

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    Method of treating incontinence
    4.
    发明授权
    Method of treating incontinence 失效
    治疗失禁的方法

    公开(公告)号：US06987107B2

    公开(公告)日：2006-01-17

    申请号：US10055663

    申请日：2002-01-23

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson

    IPC分类号： A61K31/44

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（N 1 O）/去甲肾上腺素（KI）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀等 优选光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    METHOD OF TREATING ATTENTION DEFICIT DISORDER
    6.
    发明申请
    METHOD OF TREATING ATTENTION DEFICIT DISORDER 审中-公开
    治疗缺陷性疾病的方法

    公开(公告)号：US20090247528A1

    公开(公告)日：2009-10-01

    申请号：US12430244

    申请日：2009-04-27

    申请人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31/5375 ,  A61P25/00

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。该化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。